130 related articles for article (PubMed ID: 10890189)
1. Octreotide improved ventricular arrhythmia in an acromegalic patient.
Suyama K; Uchida D; Tanaka T; Saito J; Noguchi Y; Nakamura S; Tatsuno I; Saito Y; Saeki N
Endocr J; 2000 Mar; 47 Suppl():S73-5. PubMed ID: 10890189
[TBL] [Abstract][Full Text] [Related]
2. Improvement of ventricular arrhythmia by octreotide treatment in acromegalic cardiomyopathy.
Tachibana H; Yamaguchi H; Abe S; Sato T; Inoue S; Abe S; Yamaki M; Kubota I
Jpn Heart J; 2003 Nov; 44(6):1027-31. PubMed ID: 14711197
[TBL] [Abstract][Full Text] [Related]
3. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
4. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
6. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
[TBL] [Abstract][Full Text] [Related]
7. Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study.
Shen M; Shou X; Wang Y; Zhang Z; Wu J; Mao Y; Li S; Zhao Y
Endocr J; 2010; 57(12):1035-44. PubMed ID: 21099129
[TBL] [Abstract][Full Text] [Related]
8. A patient with acromegaly who showed remarkable improvement of hyperglycemia after treatment with octreotide.
Hirose T; Kuroda T; Otsuki M; Takagi M; Yamamoto H; Motomura T; Kurebayashi S; Miyashita Y; Koga M; Arita N; Hayakawa T; Kishimoto T; Kasayama S
Intern Med; 1997 May; 36(5):345-50. PubMed ID: 9213172
[TBL] [Abstract][Full Text] [Related]
9. [A Case of Acromegaly in which a Pituitary Gland Tumor was Reduced Significantly by Administering Octreotide Long Acting Release (LAR) and Could Be Removed Surgically].
Arao T; Okada Y; Uemura F; Nishizawa S; Tanaka Y
J UOEH; 2017; 39(3):241-245. PubMed ID: 28904276
[TBL] [Abstract][Full Text] [Related]
10. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
van der Lely AJ; Muller A; Janssen JA; Davis RJ; Zib KA; Scarlett JA; Lamberts SW
J Clin Endocrinol Metab; 2001 Feb; 86(2):478-81. PubMed ID: 11157994
[TBL] [Abstract][Full Text] [Related]
11. Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR.
Resmini E; Murialdo G; Giusti M; Boschetti M; Minuto F; Ferone D
J Endocrinol Invest; 2005 Feb; 28(2):166-9. PubMed ID: 15887864
[TBL] [Abstract][Full Text] [Related]
12. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
13. [Experience in treating acromegalic patients with long-acting octreotide].
Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
[TBL] [Abstract][Full Text] [Related]
14. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery.
Lucas-Morante T; García-Uría J; Estrada J; Saucedo G; Cabello A; Alcañiz J; Barceló B
J Neurosurg; 1994 Jul; 81(1):10-4. PubMed ID: 8207509
[TBL] [Abstract][Full Text] [Related]
15. Octreotide suppresses the incretin glucagon-like peptide (7-36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects.
Plöckinger U; Holst JJ; Messerschmidt D; Hopfenmüller W; Quabbe HJ
Eur J Endocrinol; 1999 Jun; 140(6):538-44. PubMed ID: 10377503
[TBL] [Abstract][Full Text] [Related]
16. [Outcome of somatostatin analogue treatment in acromegaly].
Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
[TBL] [Abstract][Full Text] [Related]
17. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[TBL] [Abstract][Full Text] [Related]
19. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
20. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance.
Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Della Morte AM; Pivonello R; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 2001 Apr; 86(4):1551-7. PubMed ID: 11297582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
